Onconic Therapeutics will move to expand global business partnerships, led by its anticancer drug candidate "Nesuparib."
Onconic Therapeutics said on the 12th that it will take part in Bio USA 2026, to be held in San Diego from the 22nd to the 25th (local time), to conduct corporations presentations and business meetings.
On the 24th, Chief Executive Kim Jon will give a corporations presentation to introduce the research and development status and clinical results of Nesuparib, as well as the global commercialization strategy. The company plans to form a delegation of business development (BD) staff, researchers, and executives to hold partnering meetings with global pharmaceutical companies and investment institutions.
Nesuparib is an anticancer drug candidate with a dual mechanism that simultaneously inhibits PARP and tankyrase. Phase 2 clinical development is underway for four indications: pancreatic cancer, endometrial cancer, ovarian cancer, and gastric cancer.
Onconic Therapeutics presented Phase 1b clinical results of Nesuparib for patients with metastatic pancreatic cancer at the American Society of Clinical Oncology (ASCO) 2026 last month. According to the company, cases were confirmed in which complete response (CR) status was maintained for more than 40 months in some patients.
The company plans to use this Bio USA as an opportunity to expand business cooperation, as requests for partnering meetings from overseas pharmaceutical companies have increased since the ASCO presentation.
Kim said, "Global interest in Nesuparib has been rising since the ASCO presentation," adding, "We plan to discuss various cooperation plans with overseas partners."
Bio USA is the world's largest biotech and pharmaceutical industry event hosted by the Biotechnology Innovation Organization (BIO). It is considered a representative partnering event where global pharmaceutical companies, biotechs, investment institutions, and research institutions participate to discuss technology transfers, joint development, and investment attraction.